drugset
drugset / Trial / NCT02211014

An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma

NCT02211014 ↗

Phase 1 Completed 27 enrolled Acerta Pharma BV
RandomizedParallel-groupOpen-labelTreatment

Summary

To characterize the safety profile of acalabrutinib with and without dexamethasone in subjects with relapsed or refractory Multiple Myeloma (MM)

Timeline

Start
2015-02
Primary completion
2019-04-26
Completion
2019-04-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Acalabrutinib Small molecule 100 mg —

Indications

plasma cell myeloma